May 23 |
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
|
May 21 |
Blueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 year
|
May 14 |
Blueprint Medicines started at buy by Stephens, citing Ayvakit franchise
|
May 7 |
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
|
May 6 |
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
|
May 4 |
Blueprint Medicines: Rampant Growth Mostly Priced In
|
May 3 |
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript
|
May 3 |
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
|
May 3 |
Blueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ...
|
May 3 |
Q1 2024 Blueprint Medicines Corp Earnings Call
|